TY - JOUR
T1 - Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
AU - Sanmamed, Miguel F.
AU - Rodriguez, Inmaculada
AU - Schalper, Kurt A.
AU - Oñate, Carmen
AU - Azpilikueta, Arantza
AU - Rodriguez-Ruiz, Maria E.
AU - Morales-Kastresana, Aizea
AU - Labiano, Sara
AU - Pérez-Gracia, Jose L.
AU - Martín-Algarra, Salvador
AU - Alfaro, Carlos
AU - Mazzolini, Guillermo
AU - Sarno, Francesca
AU - Hidalgo, Manuel
AU - Korman, Alan J.
AU - Jure-Kunkel, Maria
AU - Melero, Ignacio
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here, we report the development of a humanized murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimulatory monoclonal antibodies (mAb) in settings where the receptors targeted by the mAbs are expressed. Human lymphocytes transferred into immunodeficient mice underwent activation and redistribution to murine organs, where they exhibited cellsurface expression of hCD137 and hPD-1. Systemic lymphocyte infiltrations resulted in a lethal CD4+ T cell-mediated disease (xenograft-versus-host disease), which was aggravated when murine subjects were administered clinical-grade anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab). In mice engrafted with human colorectal HT-29 carcinoma cells and allogeneic human peripheral blood mononuclear cells (PBMC), or with a patientderived gastric carcinoma and PBMCs from the same patient, we found that coadministration of urelumab and nivolumab was sufficient to significantly slow tumor growth. Correlated with this result were increased numbers of activated human T lymphocytes producing IFNγ and decreased numbers of human regulatory T lymphocytes in the tumor xenografts, possibly explaining the efficacy of the therapeutic regimen. Our results offer a proof of concept for the use of humanized mouse models for surrogate efficacy and histology investigations of immune checkpoint drugs and their combinations.
AB - A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here, we report the development of a humanized murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimulatory monoclonal antibodies (mAb) in settings where the receptors targeted by the mAbs are expressed. Human lymphocytes transferred into immunodeficient mice underwent activation and redistribution to murine organs, where they exhibited cellsurface expression of hCD137 and hPD-1. Systemic lymphocyte infiltrations resulted in a lethal CD4+ T cell-mediated disease (xenograft-versus-host disease), which was aggravated when murine subjects were administered clinical-grade anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab). In mice engrafted with human colorectal HT-29 carcinoma cells and allogeneic human peripheral blood mononuclear cells (PBMC), or with a patientderived gastric carcinoma and PBMCs from the same patient, we found that coadministration of urelumab and nivolumab was sufficient to significantly slow tumor growth. Correlated with this result were increased numbers of activated human T lymphocytes producing IFNγ and decreased numbers of human regulatory T lymphocytes in the tumor xenografts, possibly explaining the efficacy of the therapeutic regimen. Our results offer a proof of concept for the use of humanized mouse models for surrogate efficacy and histology investigations of immune checkpoint drugs and their combinations.
UR - http://www.scopus.com/inward/record.url?scp=84942944907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942944907&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-3510
DO - 10.1158/0008-5472.CAN-14-3510
M3 - Article
C2 - 26113085
AN - SCOPUS:84942944907
SN - 0008-5472
VL - 75
SP - 3466
EP - 3478
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -